Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
Adrian Towse and
Occasional Papers from Office of Health Economics
This paper examines the potentially positive impact of differential pricing in Europe and the overall negative effects of international reference pricing (IRP) measures. The authors point out that IRP actually encourages higher prices in lower-income countries, can delay marketing/patient access in lower-price countries, and ultimately translates into less investment in R&D. Differential pricing assumes that countries with lower incomes should pay lower prices, encourages the earliest possible marketing in all countries, and provides incentives for innovation.
Keywords: Economics; of; innovation (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2) Track citations by RSS feed
Downloads: (external link)
https://www.ohe.org/system/files/private/publicati ... Europe_11-2-2011.pdf (application/pdf)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:ohe:occpap:000191
Access Statistics for this paper
More papers in Occasional Papers from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ().